Yazar "Topuz, Samet" seçeneğine göre listele

Listeleniyor 1 - 4 / 4
  • Küçük Resim Yok
    Öğe
    Factors related to recurrence after pathological complete response to postoperative chemotherapy in patients with epithelial ovarian cancer
    (Pensiero Scientifico Editor, 2009) Karagol, Hakan; Saip, Pinar; Eralp, Yesim; Topuz, Samet; Berkman, Sinan; Ilhan, Ridvan; Topuz, Erkan
    Aims and background. It has been appreciated for some time that the lack of detection of ovarian cancer at clinical and pathological (second-look laparotomy) evaluation is not synonymous with cure. The goal of this study was to define clinical risk factors for recurrence after complete pathological response to postoperative chemotherapy in patients with epithelial ovarian cancer. Methods. Fifty-seven patients who met the inclusion criteria of our study were evaluated. The characteristics (age, menopausal status, histological subtype, tumor grade, presence of ascites at diagnosis, type of omentectomy, FIGO stage, and residual tumor volume after primary surgery) of patients with and those Without tumor recurrence were compared. Results. The median follow-up was 52 months (range, 15-142 months). The overall survival rates of the patients were 100%, 96%, and 87% at 1, 3 and 5 years, respectively At the time of the study analysis, 21 of 57 (37%) patients had recurrent disease. The median time to recurrence was 16 months. Recurrences were most frequent in the pelvis and abdominal cavity (38%). Age, menopausal status, stage at diagnosis, and residual tumor volume after initial surgery were significantly related to the risk of recurrence in univariate analysis (P = 0.039, 0.038, 0.004, and 0.000, respectively). Residual tumor volume after initial surgery-was found to be the only significant independent prognostic factor (P = 0.049, HR: 0.16, 95% CI: 0.02-0.99). Conclusion. We believe it is necessary to conduct randomized studies on this issue because insight into predictors of recurrence after pathological complete response to postoperative chemotherapy could be used to select patients for trials of consolidation therapy.
  • Küçük Resim Yok
    Öğe
    Factors related with recurrence after complete pathologic response to post- operative chemotherapy in patients with epithelial ovarian cancer
    (Elsevier, 2006) Karagol, Hakan; Saip, Pinar; Uygun, Kazim; Eralp, Yesim; Topuz, Samet; Berkman, Sinan; Ilhan, Ridvan
    [Abstract Not Available]
  • Küçük Resim Yok
    Öğe
    Optimal Cytoreduction is an Independent Prognostic Factor in Ovarian Carcinosarcoma: A Turkish Gynecologic Oncology Group Study
    (2020) Taşkın, Salih; Çoban, Gonca; Ayhan, Ali; Topuz, Samet; Akbayır, Özgür; Şahin, Hanifi; Sarı, Mustafa Erkan
    Objective: To determine prognostic factors for women with ovarian carcinosarcoma (OCS). Material and Methods: A multicenter, retrospective department database review was performed to identify patients with OCS at eight gynecologic oncology centers inTurkey. Demographic, clinicopathological, and survival data were collected. Results: We identified 94 patients with OCS. The median agewas 60.0 years (range, 31-78), and the median follow-up duration was 36.0 months (range, 4-188). After primary cytoreductive surgery, 61(64.9%) patients had ?1 cm of residual disease (optimal debulking), whereas 33 (35.1%) had >1 cm of residual disease (suboptimal debulking). For the entire cohort, the 5-year progression free survival (PFS) rate was 25.2%, whereas the 5-year overall survival (OS) rate was49.4%. Women with optimal cytoreduction had a median PFS of 41.0 months (95% Confidence Interval [CI]: 19.71-62.28, Standard Error [SE]:10.86) compared with women with suboptimal cytoreduction who had a median PFS of 15.0 months (95% CI: 8.79-21.21, SE: 3.16; p=0.011).The 5 year OS rate for women with optimal cytoreduction was significantly higher than that of women with suboptimal debulking (57.6% vs.33.9%; p=0.005). Positive peritoneal cytology (hazard ratio [H]: 2.35, 95% CI: 1.19-4.63; p=0.013) and suboptimal cytoreduction (H: 2.61,95% CI: 1.32-4.99; p=0.004) were independent risk factors for decreased OS. Conclusion: Suboptimal cytoreduction seems to be an independent prognostic factor for decreased OS in women with OCS.
  • Küçük Resim Yok
    Öğe
    Ovarian carcinosarcomas: Clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum
    (Academic Press Inc Elsevier Science, 2008) Cicin, Irfan; Saip, Pinar; Eralp, Yesirn; Selam, Meltern; Topuz, Samet; Ozluk, Yasernin; Aydin, Yucel
    Objective. To evaluate the clinicopathological prognostic factors and outcome of chemotherapy in ovarian carcinosarcomas. Methods. We reviewed the records of 26 patients treated from 1990 to 2006 at the Oncology Institute of Istanbul University. Clinical data including demographics, stage, surgery, chemotherapy, and survival were collected from patients' charts. Results. All patients underwent initial debulking surgery. Optimal debulking was achieved in 21 (81%) patients. The most striking clinicopathological finding was the high incidence of hemorrhagic ascites (n: 6) which was observed in 60% of the patients with ascites (n: 10). The overall median survival of the patients was 26 months. Residual disease was associated with a decreased overall survival, P=0.04. Median survival (50 months vs 9.7 months, P=0.042) of the patients with early stage disease were longer than the patients with advanced stage. Twenty-two patients received platinum-based combination chemotherapy. There was a trend for increased median survival in the patients who were treated with carboplatin/paclitaxel combination (P=0.066). Although the numbers were insufficient for statistical evaluation, the patients treated with ifosfamide combinations had improved survival (36 months vs 26 months). However, when the patients treated with ifosfamide and carboplatin/ paclitaxel combinations were combined, survival was statistically improved compared to the other regimens (36 months vs 9.7 months, P=0.04). Chemotherapy regimens containing doxorubicin or cyclophosphamide were not encouraging. Stage (P=0.02) and adjuvant platinum-based chemotherapy containing either paclitaxel or ifosfamide (P=0.024) remained predictive of outcome in the multivariate analysis. Conclusions. Hemorrhagic ascites can be used in the initial differential diagnosis of ovarian carcinosarcomas. Stage, optimal debulking and type of adjuvant therapy were statistically significant prognostic predictors of ovarian carcinosarcomas. We advise that patients with ovarian carcinosarcomas should be treated by optimal cytoreduction followed by adjuvant platinum/taxan or platinum/ifosfamide combinations. C 2007 Elsevier Inc. All rights reserved.